全文获取类型
收费全文 | 6191篇 |
免费 | 355篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 65篇 |
儿科学 | 360篇 |
妇产科学 | 285篇 |
基础医学 | 810篇 |
口腔科学 | 125篇 |
临床医学 | 640篇 |
内科学 | 1606篇 |
皮肤病学 | 73篇 |
神经病学 | 642篇 |
特种医学 | 131篇 |
外国民族医学 | 1篇 |
外科学 | 621篇 |
综合类 | 34篇 |
一般理论 | 3篇 |
预防医学 | 442篇 |
眼科学 | 62篇 |
药学 | 306篇 |
中国医学 | 7篇 |
肿瘤学 | 350篇 |
出版年
2023年 | 44篇 |
2022年 | 67篇 |
2021年 | 187篇 |
2020年 | 88篇 |
2019年 | 162篇 |
2018年 | 190篇 |
2017年 | 126篇 |
2016年 | 127篇 |
2015年 | 129篇 |
2014年 | 187篇 |
2013年 | 277篇 |
2012年 | 373篇 |
2011年 | 353篇 |
2010年 | 193篇 |
2009年 | 194篇 |
2008年 | 319篇 |
2007年 | 330篇 |
2006年 | 314篇 |
2005年 | 302篇 |
2004年 | 323篇 |
2003年 | 244篇 |
2002年 | 253篇 |
2001年 | 143篇 |
2000年 | 170篇 |
1999年 | 135篇 |
1998年 | 76篇 |
1997年 | 52篇 |
1996年 | 53篇 |
1995年 | 23篇 |
1994年 | 34篇 |
1993年 | 43篇 |
1992年 | 74篇 |
1991年 | 84篇 |
1990年 | 80篇 |
1989年 | 85篇 |
1988年 | 77篇 |
1987年 | 81篇 |
1986年 | 46篇 |
1985年 | 59篇 |
1984年 | 35篇 |
1983年 | 50篇 |
1982年 | 22篇 |
1981年 | 23篇 |
1979年 | 42篇 |
1978年 | 31篇 |
1976年 | 28篇 |
1975年 | 17篇 |
1974年 | 29篇 |
1973年 | 25篇 |
1972年 | 24篇 |
排序方式: 共有6563条查询结果,搜索用时 15 毫秒
1.
2.
Ariel Paracampo Marina Solis Carlos Bonetto 《International journal of environmental health research》2015,25(1):96-103
Chlorpyrifos is the most used insecticide in Argentina. Cnesterodon decemmaculatus is a widely distributed, endemic fish from Neotropical America. It attains high densities in the shallow water assemblages of Argentina and Brazil. The aim of this study was to assess the acute toxicity of chlorpyrifos to C. decemmaculatus. The mean 96-h LC50 of three independent determinations was 105.3 (±?3.1) μg/L. Sublethal effects were observed. Swimming behavioral changes at each chlorpyrifos exposure concentration were reported. C. decemmaculatus represents a good model for ecotoxicological risk assessment. 相似文献
3.
4.
5.
6.
7.
In preventive medicine and occupational health, decision-makers face uncertainty, divergent opinions, and varying needs. In the Swiss aluminum industry, screening for industrial fluorosis illustrates how decision analysis and cost-effectiveness analysis can provide rational and explicit models of decision-making in such contexts. Data on fluoride-exposed potroom workers are used to compare the cost-effectiveness of two strategies: mass screening of fluorosis versus individual detection of the disease on the basis of the worker's symptoms. A decision-analysis and a sensitivity analysis are performed to assess the impact of the screening program for different levels of expected prevalence of the disease. The optimal decision, in economic terms, is the one that minimizes the pension and screening-related costs and maximizes the number of years of full working capacity. Swiss data suggest that a diagnosis of clinical fluorosis is unlikely before 10 years of exposure to fluoride. Between 10 and 30 years of exposure to fluoride, mass screening may be more cost-effective than individual detection of the disease, even when the expected prevalence of the disease in a given industrial setting is less than 10%. 相似文献
8.
Peter L. Forster Frank B. Schoenfeld Charles R. Marmar Ariel Janna Lang 《Journal of traumatic stress》1995,8(1):143-149
Irritability is often a problem for patients with Post-Traumatic Stress Disorder (PTSD). We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts. These cases are discussed in the context of evidence that lithium may be useful in other patients with disorders of impulse control. The evidence linking disorders of anger and impulse control to a dysregulation in neurotransmitter regulation, particularly in serotonergic pathways, supports a psychopharmacologic approach to treatment. These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD. 相似文献
9.
Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy 总被引:5,自引:3,他引:2
下载免费PDF全文
![点击此处可从《Canadian Medical Association journal》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J M Moutquin P R Garner R F Burrows E Rey M E Helewa I R Lange S W Rabkin 《Canadian Medical Association journal》1997,157(7):907-919
OBJECTIVE: To provide Canadian physicians with comprehensive, evidence-based guidelines for the nonpharmacologic management and prevention of gestational hypertension and pre-existing hypertension during pregnancy. OPTIONS: Lifestyle modifications, dietary or nutrient interventions, plasma volume expansion and use of prostaglandin precursors or inhibitors. OUTCOMES: In gestational hypertension, prevention of complications and death related to either its occurrence (primary or secondary prevention) or its severity (tertiary prevention). In pre-existing hypertension, prevention of superimposed gestational hypertension and intrauterine growth retardation. EVIDENCE: Articles retrieved from the pregnancy and childbirth module of the Cochrane Database of Systematic Reviews; pertinent articles published from 1966 to 1996, retrieved through a MEDLINE search; and review of original randomized trials from 1942 to 1996. If evidence was unavailable, consensus was reached by the members of the consensus panel set up by the Canadian Hypertension Society. VALUES: High priority was given to prevention of adverse maternal and neonatal outcomes in pregnancies with established hypertension and in those at high risk of gestational hypertension through the provision of effective nonpharmacologic management. BENEFITS, HARMS AND COSTS: Reduction in rate of long-term hospital admissions among women with gestational hypertension, with establishment of safe home-care blood pressure monitoring and appropriate rest. Targeting prophylactic interventions in selected high-risk groups may avoid ineffective use in the general population. Cost was not considered. RECOMMENDATION: Nonpharmacologic management should be considered for pregnant women with a systolic blood pressure of 140-150 mm Hg or a diastolic pressure of 90-99 mm Hg, or both, measured in a clinical setting. A short-term hospital stay may be required for diagnosis and for ruling out severe gestational hypertension (preeclampsia). In the latter case, the only effective treatment is delivery. Palliative management, dependent on blood pressure, gestational age and presence of associated maternal and fetal risk factors, includes close supervision, limitation of activities and some bed rest. A normal diet without salt restriction is advised. Promising preventive interventions that may reduce the incidence of gestational hypertension, especially with proteinuria, include calcium supplementation (2 g/d), fish oil supplementation and low-dose acetylsalicylic acid therapy, particularly in women at high risk for early-onset gestational hypertension. Pre-existing hypertension should be managed the same way as before pregnancy. However, additional concerns are the effects on fetal well-being and the worsening of hypertension during the second half of pregnancy. There is, as yet, no treatment that will prevent exacerbation of the condition. VALIDATION: The guidelines share the principles in consensus reports from the US and Australia on the nonpharmacologic management of hypertension in pregnancy. 相似文献
10.
Gary Coleman Tom A. Gardiner Ariel Boutaud Alan W. Stitt 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2007,245(4):581-587
Background A recombinant form of the α2(IV)NC1 domain of type IV collagen has been shown to have potent anti-angiogenic activity although
this peptide has not been studied in the context of proliferative retinopathies. In the current investigation we examined
the potential for α2(IV)NC1 to regulate retinal microvascular endothelial cell function using a range of in vitro and in vivo
assay systems.
Materials and methods α2(IV)NC1 at concentrations between 0.1 and 1 μg/ml was added to retinal microvascular endothelial cells (RMECs) followed
by assessment of cell attachment, proliferation and survival. This agent was also tested within a novel in vitro three-dimensional
retinal angiogenesis assay and the number of angiogenic sprouts quantified. α2(IV)NC1 was also delivered intra-vitreally to
mice with oxygen-induced proliferative retinopathy (OIR) and neovascularisation evaluated in comparison with vehicle-treated
controls.
Results RMECs treated with α2(IV)NC1 (0.1, 0.5 and 1 μg/ml) showed delayed attachment at 3 h post-seeding, although this deficit had
been restored at the 6-h time point. BrdU assay of DNA replication revealed that confluent RMECs treated with α2(IV)NC1 showed
no measurable response in comparison with vehicle-treated controls. By contrast, proliferation of sub-confluent RMECs was
significantly reduced by α2(IV)NC1 at 0.5 μg/ml (P<0.01). α2(IV)NC1 also induced apoptosis in RMECs and inhibited angiogenesis of pre-existing retinal vascular networks in
vitro (P<0.001). Intra-vitreal injection of α2(IV)NC1 in the OIR model significantly inhibited pre-retinal neovascularisation compared
with vehicle-treated controls (P<0.001).
Conclusion α2(IV)NC1 inhibits angiogenesis in the retinal microvasculature. This recombinant protein has potential for the treatment
of neovascularisation in proliferative retinopathies.
BioStratum Inc. did not sponsor this research in any way. None of the authors are paid consultants with this company. 相似文献